Home' Australian Pharmacist : Australian Pharmacist Oct 2013 Contents Australian Pharmacist October 2013 I © Pharmaceutical Society of Australia Ltd.
BUSINESS AND INDUSTRY NEWS
The Business of Health Research Network
was launched recently when network
members meet with government,
business and health advocacy groups and
community representatives to ‘prioritise
research at the interface of business
‘ The link between health and business
is very strong,’ the Network’s co-leader
Professor Corinne Mulley said.
‘For example, the obesity debate embraces
marketing, branding, advertising and food
retailing and involves the private sector
as well as public health advocates, policy
makers and consumers.
The Network’s other co-leader, Associate
Professor Teresa Davis, said, ‘We expect
to examine every aspect of this debate
from consumer behaviour to attitudes
towards exercise through to the role of
‘Our intension is to bridge the gap between
industry and the community on this issue.’
The market for nanomedicine-based
oncology drugs is projected to grow from
$5.5 billion in 2011 to $12.7 billion in 2016
and interest in the development of novel
delivery solutions to enhance cancer
therapy is intense.
The Monash Institute of Pharmaceutical
Sciences (MIPS) has collocated chemistry,
drug delivery and cancer biology within
the institute to provide an ideal scientific
and intellectual environment to probe
the complex interactions between drug
delivery systems and the biological
environment at the nanoscale relevant to
MIPS has a long-standing interest in this
research field and our activities have
recently been bolstered by a number of
significant advances including:
• Recruitment of Professor Tom Davis
and Dr Michael Whittaker, from the
Australian Centre for Nanomedicine
at UNSW, and Dr Angus Johnston,
from The University of Melbourne, to
spearhead the University’s efforts in
• Initiation of a major collaboration with
Warwick University in the UK, one of the
premier international polymer chemistry
groups, to form a highly significant
cross-university focus of activity in next
generation polymeric nanomedicines.
• A recent $548,000 ARC linkage grant
led by Professor Chris Porter (along
with Doctors Kaminskas, Boyd, Sloan
and Bunnett) and their biotechnology
partner Starpharma Limited,
to advance design and evaluation of
dendrimer-based delivery systems to
target drug delivery.
This content is for information purposes only. The clinical information presented should not be used to
guide clinical advice/decisions without reference to the complete section of the APF.
What can I find out about...
You can find all this and more in the complete
corticosteroids manuscript in your APF22.
See pages 157–159 and 594–595.
Visit www.psa.org.au to purchase your copy.
Accreditation number: CAP131010h
This activity has been accredited for 0.25 hours of Group 2 CPD
(or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan.
How well do I understand the optimal use of available
Based on the information in APF22, Which of the following statements about the use of
corticosteroids is MOST appropriate?
a) A dose of budesonide 200 mcg two puffs twice daily has approximately the same potency as
beclomethasone 400 mcg one puff twice daily.
b) A professional athlete is permitted to use 3 mg oral dexamethasone daily during competition as an
equivalent alternative to a short course of 20 mg oral prednisone, which is prohibited in sport.
c) If betamethasone dipropionate 0.05% cream is out of stock, it may be appropriate to recommend
that the doctor change the prescription to betamethasone valerate 0.1% cream.
d) Growth suppression is highly likely for an 8-year-old boy taking inhaled
beclomethasone doses of 600 mcg daily
Enter your answer and claim 0.5 Group 2 CPD credits.
Visit www.psa.org.au and click submit answers.
When is adrenal
suppression more likely
to occur with systemic
Adrenal suppression is more likely to
occur with pharmacological doses used
for longer than two to three weeks.
Glucocorticoid doses should not be
discontinued abruptly if there is a risk
of significant adrenal suppression.
For people requiring long-term
corticosteroid therapy, changing
therapy from a daily to an alternate
day regimen can reduce the risk of
adverse reactions and toxicity and allow
recovery of the HPA axis function.
How does the ‘fingertip
unit’ rule apply to the use of
It is recommended that topical
corticosteroids be applied according
to the ‘fingertip unit’ (FTU) rule.
One FTU (the distance between the
tip of the finger and the crease of
the first joint) should cover an area
equivalent to two palmar surfaces on
the patient’s body. One FTU in an adult
is approximately 0.5 g.
Links Archive Australian Pharmacist Sept 2013 Australian Pharmacist Nov 2013 Navigation Previous Page Next Page